← All trials
NCT05115513
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Nov 10, 2021
- Last posted
- Nov 10, 2021
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yale UniversityLead sponsor
- Yale UniversityReponsible party - principal investigator
- Yale UniversityOverall official - principal investigator
- National Institute on Drug Abuse (NIDA)Collaborator
- University of ConnecticutCollaborator
- NHTSACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.